Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II study of CS1 in patients undergoing orthopedic surgery

Trial Profile

A Phase II study of CS1 in patients undergoing orthopedic surgery

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valproic acid (Primary)
  • Indications Thrombosis
  • Focus Therapeutic Use

Most Recent Events

  • 30 Mar 2020 According to a Cereno Scientific media release, due to the global spread of the Sars-cov-2 virus, the company will postpone this planned trial. The start of the study was previously planned for mid-year 2020. Cereno Scientific is adjusting planned activities to start by the end of the year, but is prepared for further adjustments if needed, due to the uncertainty of the further development of the pandemic.
  • 27 Feb 2020 According to a Cereno Scientific media release, the company expects to initiate this trial in mid-year 2020.
  • 27 Feb 2020 According to a Cereno Scientific media release, the authorities in Bulgaria have issued approval regarding the company's application to initiate this trial on 19th November 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top